| Oncology | Cardiovascular & Metabolics | Autoimmune | Pain | Other | |
| Apatinib VEGFR2 Gastric Cancer/HCC |
Mecapegfilgrastim ★ PEG-G-CSF Neutropenia |
Retagliptin DPP-4 Type II Diabetes |
Hetrombopag TPOR ITP/Aplastic Anemia |
Imrecoxib COX-2 Osteoarthritis |
SHR8028 Calcineurin DED |
| Pyrotinib EGFR/HER2/HER4 HER2+ Breast Cancer |
Camrelizumab ★ PD-1 CHL/HCC/EC/NSCLC/NPC |
Henagliflozin SGLT2 Type II Diabetes |
SHR4640 URAT1 Gout/Hyperuricemia |
Remimazolam GABAα Gastroscopy Sedation/ Colonoscopy Sedation |
SHR8058 Lipid Regulator DED |
| Fuzuloparib PARP BRCAm OC |
Fuzuloparib PARP Recurrent OC Maintenance |
SHR20004 ★ GLP-1 (SC) Metabolic Diseases |
SHR0302 JAK1 RA/AS |
Remimazolam GABAα General Anaesthesia |
DDO-3055 HIF-PH Renal Anemia |
| Fuzuloparib PARP OC/BC/Pancreatic Cancer |
SHR6390 CDK4/6 Breast Cancer |
SHR-1209 ★ PCSK9 Hypercholesterolemia |
SHR-1314 ★ IL-17 AS/PsO |
Remimazolam GABAα Fibrobronchoscope Sedation |
SHR-1222 ★ SOST Osteoporosis |
| Pyrotinib EGFR/HER2/HER4 HER2m NSCLC |
SHR3680 AR Prostate Cancer |
INS068 ★ Basal Insulin Diabetes |
SHR0302 JAK1 AD/UC/CD/AA |
SHR0410 KOR Analgesia |
SHR-1707 ★ Aβ Alzheimer’s Disease |
| SHR-1316 ★ PD-L1 SCLC/NSCLC |
Famitinib VEGFR2/c-Kit/PDGFR GIST |
SHR0532 ROMK Hypertension |
SHR-1703 ★ IL-5 Asthma |
SHR8554 MOR Analgesia |
|
| Pyrotinib EGFR/HER2/HER4 HER2m BTC |
SHR-1701 ★ PD-L1/TGF-β Pancreatic Cancer/NSCLC |
SHR2285 FXI Anticoagulation |
Anti-Infection | ||
| SHR1459 BTK Lymphoma |
SHR-A1811 ★ HER2 ADC Solid Tumors |
SHR7280 GnRH Endometriosis |
SHR8008 CYP51 RVVC/VVC |
||
| SHR2554 EZH2 Lymphoma |
SHR-1802 ★ LAG-3 Solid Tumors |
HRS9950 TLR8 HBV |
|||
| SHR-1702 ★ TIM-3 Solid/Hematological Tumors |
SHR-1501 ★ IL-15 Solid Tumors |
HRS5091 Core Protein HBV |
|||
| SHR-1916 ★ PEG-IL-2 Advanced Tumors |
|||||
| Launched | |||||
| NDA | |||||
| Phase III | |||||
| ★ Large Molecule | Phase II | ||||
| Phase I | |||||
| Oncology | Autoimmune | Pain | Other | |
| Camrelizumab ★ + Apatinib PD-1+VEGFR2 HCC (1L) [A,C,F] |
Pyrotinib EGFR/HER2/HER4 HER2m NSCLC [A,C,F] |
SHR-1314 ★ IL-17 Psoriasis [A,D] |
SHR0410 KOR Analgesia/Pruritus [D] |
SHR80284 Calcineurin DED [A] |
| SHR3680+ADT AR+ADT MHSPC [C] |
Fuzuloparib PARP 1L mCRPC [A,C,D,F] |
SHR0302 JAK1 UC/CD [A,C] |
SHR80584 Lipid Regulator DED [A] |
|
| Camrelizumab★+Famitinib PD-1+VEGFR2/c-Kit/PDGFR Solid Tumors [A] |
SHR-A1811 ★ HER2 ADC Solid Tumors [A,D,E,F] |
SHR0302 JAK1 AA [A,D] |
SHR-1707 ★ Aβ Alzheimer’s Disease [D] |
|
| SHR-1316 ★ PD-L1 Solid Tumors [D] |
SHR-1701 ★ PD-L1/TGF-β Solid Tumors [D,F] |
SHR03022 JAK1 Hand Eczema [A,B,D] |
Anti-Infection | |
| Fuzuloparib PARP Solid Tumors [D] |
SHR3680 AR MCRPC [D] |
SHR4640 URAT1 Gout [D] |
SHR80083 CYP51 RVVC [A,B,C,E] |
|
| SHR-1316★ +SHR-1501★ PD-L1+IL-15 Solid Tumors [D] |
SHR14591 BTK B-cell Malignancy [C,D] |
|||
| SHR6390 CDK 4/6 Solid Tumors [D] |
||||
| Launched | ||||
| We are seeking partners for the ex-China development and commercialization, both for assets that have vs. have not entered ex-China trials. | NDA | |||
| Phase III | ||||
| Phase II | ||||
| Notes: (1) Trial run by TG Therapeutics (out-license partner). (2) Trial run by ArcutisPharmaceuticals (out-license partner). (3) Trial run by Mycovia (in-license partner). (4) Trial run by Novaliq(in-license partner). |
★ Large Molecule | Phase I | ||
| A = USA | ||||
| B = Canada | ||||
| C = EU | ||||
| D = Australia | ||||
| E = Japan | ||||
| F = Korea | ||||
| Oncology | Metabolics | Autoimmune | ||
| Pyrotinib+Capecitabine HER2/EGFR+Chemo Breast Cancer |
Camrelizumab+Chemo PD-1+Chemo Nsq-NSCLC(1L) |
Camrelizumab+Chemo PD-1+Chemo 1L NPC |
Retagliptin+Metformin DPP-4+Metformin Type II Diabetes |
SHR8735+Immunosuppt TPOR+Immunosuppt AA |
| Camrelizumab +Apatinib PD-1+VEGFR Liver Cancer (1L)/NSCLC/GC/GEJC |
Camrelizumab+FOLFOX4 PD1+Chemo Liver Cancer (1L) |
SHR-1316 +Carboplatin+Etoposide PD-L1+Chemo ES-SCLC (1L) |
Henagliflozin+Metformin SGLT2+Metformin Type II Diabetes |
|
| Pyrotinib+Tras+Docetaxel HER2/EGFR+HER2 +Chemo BC (1L/Neoadjuvant) |
Camrelizumab+ Apatinib+Chemo PD-1+VEGFR+Chemo TNBC |
Fuzuloparib+Apatinib PARP+VEGFR HER2-Breast/ Ovarian Cancer |
Henagliflozin+Retagliptin+ Metformin SGLT2+DPP-4+ Metformin Type II Diabetes |
|
| Camrelizumab+Chemo PD-1+Chemo NSCLC/EC |
SHR6390+Letrazole CDK4/6+NSAI Breast Cancer |
SHR3680+ADT AR+ADT CRPC |
Henagliflozin+Retagliptin SGLT2+DPP-4 Type II Diabetes |
|
| SHR6390+Fulvestrant CDK4/6+SERD Breast Cancer |
Fuzuloparib+Abiraterone PARP+AR MCRPC(1L) |
Camrelizumab+Famitinib PD-1+VEGFR2/c-Kit/PDGFR RCC |
||
| Camrelizumab+Apatinib PD-1+VEGFR Lung Cancer/Liver Cancer |
Camrelizumab+Apatinib /Chemo PD-1+VEGFR/Chemo GC/GEJC |
Camrelizumab+Famitinib PD-1+VEGFR2/c- Kit/PDGFR cervical cancer/NSCLC |
||
| SHR-1701+Bevacizumab PD-L1/TGF-β+VEGF Solid Tumors |
SHR-1316+Fuzuloparib PD-L1+PARP SCLC (≥2L) |
Camrelizumab+Apatinib +Fuzuloparib PD-1+VEGFR+PARP TNBC |
||
| SHR-1316+SHR-1501 PD-L1+IL-15 Solid Tumors |
Fuzuloparib+mFOLFIRINOX PARP+Chemo Pancreatic Cancer |
Fuzuloparib+Apatinib PARP+VEGFR Ovarian Cancer/TNBC |
||
| Launched | ||||
| NDA | ||||
| Phase III | ||||
| Phase II | ||||
| Phase I | ||||
About |
R&d |
|
